Core Viewpoint - Mirxes-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and disease screening [1] - The flagship product, GASTROClear, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the FDA in the US [1] - GASTROClear has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - Guoyuan International believes that the company has significant technological, product, and market advantages in the field of miRNA-based early cancer detection, positioning it as one of the global leaders in this sector [1] - Everbright Securities International previously noted the vast market potential for global cancer screening, highlighting high industry entry barriers [1] - GASTROClear is the only approved molecular diagnostic IVD product for gastric cancer screening in the global market, holding the largest market share (66.3%) in the Southeast Asian miRNA-based liquid biopsy gastric cancer screening market as of 2023 [1]
MIRXES-B涨近9%创新高 公司在基于miRNA的癌症早期检测领域优势显著